SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (951)11/18/1997 7:00:00 PM
From: D.Right  Read Replies (1) of 2173
 
Dear Henry:

Well, if you believed that amylin should have as strong as an effect as insulin, it was totally wrong. Insulin is THE hormone in regulating the metabolism of energy. You have to have it either by injection or secreted by your own body. Insulin is the whole game. Either pramlintide or drugs like Resulin won't do any good without the proper amount of insulin in your body. The problem with insulin in patients is that you can not really get the proper amount, too much of it is very dangerous. This is where pramlintide coming to play. Of course, how good it will be in the coming trials we have to wait and see and obviously Wall Street dons not have the patient to wait for a whole year. I have given my predictions before, no need to repeat here.

As for safety, the highest dose for pramlintide was 150 microgram three times a day. For a peptide, it accounts for less than 1% of protein and peptied the body has to clear each day. There should not be any safety concern at all. Rezulin's liver problem may or may not come from the activation of its receptors in liver cells. I am sure WLA is working on it. They have to tell the FDA and diabetic patients if they know what is going on even if they may not want to share it with LLY/LGND.

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News